Ardelyx, Inc. (ARDX)
3.27
+0.08
(+2.51%)
USD |
NASDAQ |
Oct 15, 16:00
3.30
+0.03
(+0.92%)
After-Hours: 20:00
Ardelyx Cash from Operations (TTM) : -17.32M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -17.32M |
| March 31, 2026 | -36.26M |
| December 31, 2025 | -42.48M |
| September 30, 2025 | -53.62M |
| June 30, 2025 | -53.49M |
| March 31, 2025 | -47.54M |
| December 31, 2024 | -44.81M |
| September 30, 2024 | -63.34M |
| June 30, 2024 | -85.30M |
| March 31, 2024 | -80.64M |
| December 31, 2023 | -89.72M |
| September 30, 2023 | -66.72M |
| June 30, 2023 | -70.68M |
| March 31, 2023 | -87.22M |
| December 31, 2022 | -70.04M |
| September 30, 2022 | -123.80M |
| June 30, 2022 | -132.96M |
| March 31, 2022 | -135.95M |
| December 31, 2021 | -152.55M |
| September 30, 2021 | -130.67M |
| June 30, 2021 | -115.96M |
| March 31, 2021 | -100.71M |
| December 31, 2020 | -81.44M |
| Date | Value |
|---|---|
| September 30, 2020 | -74.98M |
| June 30, 2020 | -75.72M |
| March 31, 2020 | -84.52M |
| December 31, 2019 | -76.48M |
| September 30, 2019 | -83.78M |
| June 30, 2019 | -90.19M |
| March 31, 2019 | -80.38M |
| December 31, 2018 | -70.27M |
| September 30, 2018 | -47.14M |
| June 30, 2018 | -39.16M |
| March 31, 2018 | -45.23M |
| December 31, 2017 | -65.19M |
| September 30, 2017 | -96.45M |
| June 30, 2017 | -102.23M |
| March 31, 2017 | -103.05M |
| December 31, 2016 | -92.53M |
| September 30, 2016 | -87.58M |
| June 30, 2016 | -74.56M |
| March 31, 2016 | -79.88M |
| December 31, 2015 | -71.84M |
| September 30, 2015 | -54.03M |
| June 30, 2015 | -47.91M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Capricor Therapeutics, Inc. | -104.00M |
| REGENXBIO, Inc. | -246.67M |
| Compass Therapeutics, Inc. | -56.11M |
| ARS Pharmaceuticals, Inc. | -196.40M |
| Sionna Therapeutics, Inc. | -75.92M |